Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q4 FY21 Earnings Presentation
19 slides from Eris Lifesciences's earnings presentation, May 13, 2021
Slide 1: Exchange filing cover letter: Investor Presentation
Date: 13th May, 2021 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the require
Slide 2: Q4 FY 21 and FY 21 Investor Presentation
Q4 FY 21 and FY 21 INVESTOR PRESENTATION 13th May 2021 1
Slide 3: FY 21 Financial Highlights
FY 21 FINANCIAL HIGHLIGHTS Q4 FY 21 FY 21 INR mn INR mn INR mn INR mn 2,782 945 12,119 4,306 11.9% 22.4% 12.8% 16.9% Op Revenue yoy growth EBITDA yoy growth Op Revenue yoy growth EBITDA yoy growth INR mn INR mn INR 682 3,551 26.16 21.3% 19.8% 21.0% PAT yoy growth PAT yoy growth EPS yoy growth Debtor
Slide 4: FY 21 Financial Highlights (Contd..)
FY 21 FINANCIAL HIGHLIGHTS (Contd..) 87 % 81 % 33.5 % 30.7 % OCF to FCF to ROIC * ROE * EBITDA EBITDA • INR 3,754 mn Operating Cash Flow and INR 3,466 mn Free Cash Flow for FY 21; continue to be among the highest in the industry • INR 5.5 Dividend per share distributed; pay-out ratio ~ 21% of Net Pr
Slide 5: FY 21: Eris ranks among the fastest growing companies
FY 21: ERIS RANKS AMONG THE FASTEST GROWING COMPANIES (ex. Covid Molecules) FY 21 MAT Growth (excluding Covid Molecules*) 11.1% 10.5% 8.5% 6.9% 6.8% 6.2% 4.9% 4.2% 4.1% 4.0% 1.3% IPM excl. Covid IPCA Cadila Emcure* USV Aristo Eris Pfizer* Cipla Torrent Intas Molecules Source: AIOCD MAT Mar 21 *Favip
Slide 6: Q4 FY 21 – Business Highlights
Q4 FY 21 – BUSINESS HIGHLIGHTS • Eris grew at 2.0% yoy in Q4 FY 21 due to a high base effect in the core cardio metabolic and VMN segments. Cardio Metabolic VMN 22.6% 39.4% 14.1% 13.6% 12.9% 12.3% 12.0% 11.1% 15.8% 16.3% 8.2% 12.1% 13.6% 13.2% 6.2% 9.5% 7.1% -5.6% -6.9% 1.2% Q4 FY 20 Q1 FY 21 Q2 FY
Slide 7: FY 21 – Business Highlights
FY 21 – BUSINESS HIGHLIGHTS • Eris grew at 6.2% yoy in FY 21, outperforming by 2x the covered market which grew at 2.9% yoy. This is the 3rd consecutive year of Eris outperforming the covered market and the IPM. • Core Cardio metabolic and VMN segments (79% of total revenue) outperform covered marke
Slide 8: Spearheading digital dissemination of scientific knowledge
SPEARHEADING DIGITAL DISSEMINATION OF SCIENTIFIC KNOWLEDGE • As a prominent stakeholder in the enhancement of scientific knowledge, Eris conducted 2,500+ interactions in FY21 covering 36,000+ doctors • Discussion topics included developments in the cardio-metabolic segment, impact of Covid on heart
Slide 9: Strengthened prescription ranking among super-specialists
STRENGTHENED PRESCRIPTION RANKING AMONG SUPER-SPECIALISTS Eris Prescription Ranking* among Doctor Specialties 4 3 3 CARDIOLOGISTS DIABETOLOGISTS GASTROENTEROLOGISTS 3 CONSULTING 6 NEUROLOGISTS PHYSICIANS Source: SMSRC MAT Feb 2021 * Rank in Represented Market 8
Slide 10: Zomelis – robust growth since acquisition
ZOMELIS – ROBUST GROWTH SINCE ACQUISITION Dec 2019 Vildagliptin Molecule Generics’ share of molecule (%) Mar 2021 103.7 67% • Consistently ranked #1 93.4 among all (83) Gx versions 71.7 55.3 44% of Vildagliptin; #3 including 31% innovator brands 20% • 4.4x growth in Zomelis Volume Value Volume Value
Slide 11: Gluxit – successful launch in the SGLT 2 segment
GLUXIT – SUCCESSFUL LAUNCH IN THE SGLT 2 SEGMENT Ranks #1 (by value and 3.6x growth in Among the first volume) among 30+ Gx monthly sales run Generic versions versions of Dapa; rate since launch; of Dapagliflozin to be launched in Ranks #1 by volume and #3 Exit run-rate of Oct 2020 by value includin
Slide 12: Power brands leading presence in core therapies
FY 21 – POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES Therapy wide presence in Oral Diabetes Care with power brands holding high ranks in Newer-generation fast-growing molecules Sulfonylurea Glimisave rank 6 in the ≈4,500 cr Glimepiride and combinations market Glimisave MV rank 2
Slide 13: Power brands leading presence in core therapies
FY 21 – POWER BRANDS CONTINUE TO HAVE LEADING PRESENCE IN CORE THERAPIES High rank in Anti-Hypertensives: the fastest growing and largest segment of Cardiac Care Eritel rank 5 in the ≈3,500 cr Telmisartan and combinations market Eritel CH rank 4 in Telmisartan + Chlorthalidone market Eritel LN rank
Slide 14: Drivers of sustainable secular growth going forward
DRIVERS OF SUSTAINABLE SECULAR GROWTH GOING FORWARD • Our business model of building strong and sustainable brands has enabled us to not only maintain, but also expand market shares during the pandemic period when MR-Doctor interactions have been severely constrained • Prescriber preference has shif
Slide 15: Standalone Income Statement
STANDALONE INCOME STATEMENT Standalone Q4 FY 21 FY21 INR Millions Q4 FY21 Q4 FY20 FY21 FY20 YOY Gr % YOY Gr % • Operating Revenue grew by 11.3% yoy in Q4 21 and by Sale of Products 2,527 2,261 11.8% 10,886 10,038 8.5% Other Operating Income 42 47 -10.3% 202 165 22.6% 8.7% in FY 21 Revenue from Opera
Slide 16: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT Consolidated Q4 FY 21 FY21 INR Millions Q4 FY21 Q4 FY20 YOY Gr % FY21 FY20 YOY Gr % Branded Formulation Sales Sale of Products 2,743 2,441 12.4% 11,926 10,582 12.7% Q4 FY 21 FY 21 INR Millions Q4 FY 21 Q4 FY 20 FY 21 FY 20 Other Operating Income 40 45 -11.8% 192 159 21.
Slide 17: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors As on As on As on Others, 31-Mar-21 31-Dec-20 30-Sep-20 0.5% Sr no Name of Shareholder DIIs, 9.67% 605* 580* 538* Promoters 54.13% 54.23% 54.08% 1 ChrysCapital (Emerald Investment Limited) 5.51% 5.51% 5.51% 2 UTI Mutual
Slide 18: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 19: Thank You
THANK YOU KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 18